Psy Therapeutics
Psy Therapeutics is a drug discovery company focused on developing novel medicines for central nervous system (CNS) disorders, specifically targeting anxiety, depression, and dementia. They aim to improve neuropsychiatric care through a pipeline of high-potential therapeutics. The company leverages an integrated translational approach, combining advances in disease biology, chemistry, and data-driven decision-making with the expertise of leading neuropsychiatric scientists and clinicians. Their approach includes identifying validated drug targets, utilizing flexible R&D tools like DEL and machine learning, and employing rigorous translational paths and innovative clinical trial designs. Psy Therapeutics has a risk-balanced pipeline with eight drug programs, including PSY-05001 for pain and PTSD, PSY-01 for Parkinson's disease and depression, and PSY-02 for Alzheimer's disease and other tauopathies. They collaborate with industry leaders like X-Chem and IntelliSyn to enhance R&D productivity.
Psy Therapeutics
Psy Therapeutics is a drug discovery company focused on developing novel medicines for central nervous system (CNS) disorders, specifically targeting anxiety, depression, and dementia. They aim to improve neuropsychiatric care through a pipeline of high-potential therapeutics. The company leverages an integrated translational approach, combining advances in disease biology, chemistry, and data-driven decision-making with the expertise of leading neuropsychiatric scientists and clinicians. Their approach includes identifying validated drug targets, utilizing flexible R&D tools like DEL and machine learning, and employing rigorous translational paths and innovative clinical trial designs. Psy Therapeutics has a risk-balanced pipeline with eight drug programs, including PSY-05001 for pain and PTSD, PSY-01 for Parkinson's disease and depression, and PSY-02 for Alzheimer's disease and other tauopathies. They collaborate with industry leaders like X-Chem and IntelliSyn to enhance R&D productivity.